We’re on the verge of an innovation breakout. More gene therapies than ever are priming the pipeline and facing approvals, aimed to vastly improve patient lives or even cure their diseases. Join our deep bench of experts for valuable insights and lessons learned from the development of gene therapies. Understand the time and perseverance it takes by all stakeholders to develop truly innovative technologies, from the trials and tribulations that gene therapies have incurred, to what to expect from key advances ahead. For both the scientist and non-scientist alike, you will leave our forum with a deeper respect and perspective of the pioneers who led the way and those now taking the lead to further advance these significant medical therapies.
Executive in Residence at the Center for Integration of Science and Industry at Bentley University
Mike Boss has been a leader in the biotechnology industry for more than 30 years as a scientist and senior executive. As a group leader at Celltech, he was lead inventor of the landmark “Boss patent,” which enabled genetic engineering and manufacture of recombinant, monoclonal antibodies and generated >$1 billion in revenues. Dr. Boss co-founded Oros Instruments, a successful developer of protein purification equipment that was acquired by Biotage. He subsequently joined Genica Pharmaceuticals as Vice President of Research and Development and later Vice President of Operations, where he had a central role in building Genica (renamed Athena Diagnostics) into the leading developer of neurological and genetic tests. Later, Boss held the position of Vice President, Corporate Office of Technology, at Elan Corporation and Chief Operating Officer of Xanthus Pharmaceuticals Inc., leading its acquisition by Antisoma, where he continued in senior executive positions. For the past five years, Boss has led the program at Summit Therapeutics, Inc. as Chief Technology Officer to develop a therapy for Duchenne Muscular Dystrophy. Under his leadership the program progressed from pre-clinical to a proof-of-concept Phase 2 trial. He has a BSc and PhD from London University and an MBA from London Business School, trained in immunology at ICRF London with Dr. Mel Greaves and Dr. Martin Raff, and was a post-doctoral fellow with Dr. David Baltimore at the Center for Cancer Research at MIT.
Daniel Leonard is the Director of Global Patient Advocacy at uniQure, a pioneering company in gene therapy. In this role Dan works primarily with hemophilia and Huntington’s disease organizations in the US and abroad. In this role Dan serves as an ambassador to the patient community, but also as an internal advocate for patients’ interests. Prior to joining uniQure, Dan spent 16 years at Genzyme, a company known as a leader in patient centricity. Prior to transitioning to Patient Advocacy in 2011, Dan spent 11 years working in Regulatory Affairs, managing a team responsible for registering enzyme replacement therapies and small molecules throughout Asia and the Middle East. With a Masters’ Degree in Japanese Language and Literature, Dan’s primary focus was registering products in Japan. Dan is active in the non-profit world, served on the Board of Directors of an educational non-profit in Cambridge, MA and developed and launched an award-winning community engagement program bringing students into corporate labs to teach them the science of biotechnology.
Entrepreneur In Residence, Wyss Institute, CEO Ally Therapeutics
Tina Liu, M.B.A., Entrepreneur In Residence, Wyss Institute; CEO, Ally Therapeutics
Together with a scientific team led by geneticist George Church and immunologist Ying Kai Chan, Tina is spinning out Ally Therapeutics from the Wyss Institute at Harvard. Ally seeks to systematically solve the immune response issues that limit gene therapies today. Prior, Tina was a private equity investor at TPG Capital, where she evaluated potential investments $1Bn+ in size across commercial pharma and other sectors of the healthcare industry. Before that, Tina was an investment banker at Morgan Stanley, where she advised healthcare companies on key transactions including mergers and acquisitions, equity and debt financings, and other strategic alternatives. Tina received her MBA with Distinction from Harvard Business School and her BA, magna cum laude, from Harvard College.
Bill was most recently Chief Scientific Officer at CRISPR Therapeutics, establishing the company in the United States through successful financing, IPO and first clinical trial application in Europe. He has held prior senior leadership positions in both large and small bio/pharma companies. He currently serves on several corporate and scientific advisory boards, and is a consultant in the biopharma industry.
Senior Vice President Immunogenetics, Editas Medicine
Dr. Morgan has spent his career overseeing research programs focused on engineered cell medicines and gene therapies, including the development and advancement of multiple oncology medicines. He served as Vice President Immunotherapy, bluebird bio from 2013 – 2018. While at bluebird bio, Dr. Morgan’s team developed the company’s lead oncology asset bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma. Prior to his position at bluebird bio, Dr. Morgan was a Staff Scientist for the Surgery Branch of the National Cancer Institute and the Interim Chief of the Clinical Gene Therapy Branch of the National Human Genome Research Institute. Dr. Morgan is a member of the board of directors of the American Society of Gene and Cell Therapy (ASGCT), serving as the translational and clinical development representative, and he has published more than 150 scientific papers during his career. He received his Ph.D. in genetics from John Hopkins University and his B.A. in biochemistry from Brandeis University.